We don’t know how many patients will take up the offer to continue. The maximum number would be 3 from each of the four SAD cohorts, so 12. Maybe some will choose not to continue. They seem to be focusing on the younger, less advanced patients but there may be some effect on the more advanced patients with higher, repeated doses.
I guess we’ll eventually find out.
Ann: Extension of RP11 Single Dose Study Into Multiple Dose Study, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.005(0.42%) |
Mkt cap ! $691.1M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.19 | $410.5K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15611 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |